Mineralys Therapeutics, Inc. (MLYS) Stock Price & How to Invest
Short answer
MLYS is Mineralys Therapeutics, a clinical-stage biopharma whose entire investment case rides on one drug, lorundrostat, an aldosterone synthase inhibitor for uncontrolled and resistant hypertension that is under FDA review with a target decision date of December 22, 2026. It is a binary, event-driven biotech story: no product revenue yet, a well-funded balance sheet, and an approval-or-not catalyst on the near horizon.
MLYS stock price
As of 2026-07-08, Mineralys Therapeutics, Inc. (MLYS) last closed at $30.40, up 111.6% over the past year. Over the past 52 weeks it has traded between $12.87 and $47.33.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Mineralys Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Mineralys Therapeutics, Inc. (MLYS) do?
Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by dysregulated aldosterone. Its lead and essentially only asset is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor being developed for uncontrolled and resistant hypertension, with additional programs exploring chronic kidney disease (CKD) and obstructive sleep apnea (OSA). The company completed its Phase 3 program (including the Launch-HTN and Advance-HTN trials) and submitted a New Drug Application that the FDA accepted, with a PDUFA target action date of December 22, 2026, positioning Mineralys as it transitions toward a potential pre-commercial stage.
The investment picture is that of a classic binary biotech. As a pre-revenue company, Mineralys reported a net loss (roughly $39.3 million in Q1 2026) funded by a large cash position of around $646 million as of March 31, 2026, which management expects to fund operations into 2028. The stock, valued near $2.3 billion, prices in a meaningful probability of approval and commercial success for lorundrostat in a very large hypertension market. The flip side is concentration risk: a negative FDA decision, a competitive setback, or a disappointing launch would weigh heavily because there is no diversified pipeline or product revenue to cushion it.
What's driving Mineralys Therapeutics, Inc. (MLYS)?
1. Lorundrostat FDA decision
The single largest driver is the FDA review of lorundrostat, with a PDUFA target date of December 22, 2026. An approval would move Mineralys from clinical-stage to a commercial-stage company with a first-in-class-tier aldosterone synthase inhibitor. The decision is the defining catalyst for the stock over the coming year.
2. Large uncontrolled-hypertension market
Uncontrolled and resistant hypertension affects a very large patient population that remains poorly served by existing generic therapies. Lorundrostat targets aldosterone, a hormone implicated in blood pressure that current standard regimens do not directly address. If approved and adopted, even modest penetration of this market could support substantial revenue.
3. Pipeline expansion into CKD and OSA
Beyond core hypertension, Mineralys is studying lorundrostat in chronic kidney disease and obstructive sleep apnea, conditions where aldosterone dysregulation plays a role. Positive data in these adjacent indications could broaden the drug's addressable market and lengthen its commercial runway well beyond an initial hypertension label.
4. Balance sheet and launch readiness
With roughly $646 million in cash as of March 2026 and runway guided into 2028, Mineralys has capital to fund a potential launch and continued trials without immediate financing pressure. The company has also raised additional equity in 2026, adding cushion but modestly diluting existing holders.
What are the risks to Mineralys Therapeutics, Inc. (MLYS)?
The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. Competition is real, most notably AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor with strong Phase 3 data, plus other emerging candidates. As a pre-revenue biotech, Mineralys burns cash and has raised equity, creating dilution risk. Even with approval, commercial execution (payer coverage, physician adoption, and pricing in a market full of cheap generics) is uncertain. The stock is volatile and highly sensitive to trial readouts and regulatory news.
How is Mineralys Therapeutics, Inc. (MLYS) valued? (approximate, JUNE 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Mineralys Therapeutics, Inc.'s investor relations page or your broker.
- Product revenue (TTM): ~$0 (pre-commercial)
- Cash & investments: ~$646M (Mar 2026)
- Q1 2026 net loss: ~$39M
- Q1 2026 R&D expense: ~$24M
- Market cap: ~$2.3B
- Shares outstanding: ~88M (post June 2026 offering)
Standard valuation multiples do not apply to Mineralys because it has no product revenue and posts ongoing losses funded by its cash balance. The roughly $2.3 billion market value reflects the market's probability-weighted view of lorundrostat's approval and future sales, not trailing fundamentals. Cash of about $646 million as of March 2026, with runway guided into 2028, is the key financial cushion ahead of the December 2026 FDA decision.
Who competes with Mineralys Therapeutics, Inc. (MLYS)?
Aldosterone synthase inhibitor developers
The most direct competitor is AstraZeneca, whose baxdrostat is a late-stage aldosterone synthase inhibitor with strong Phase 3 hypertension data and far greater commercial scale. Other emerging candidates in this class (such as vicadrostat, tied to Boehringer Ingelheim, and dexfadrostat) compete for the same aldosterone-driven mechanism, making the class race a central dynamic for Mineralys.
Established hypertension therapies
Lorundrostat would launch into a market dominated by inexpensive generic antihypertensives (ACE inhibitors, ARBs, calcium channel blockers, diuretics) and mineralocorticoid receptor antagonists like spironolactone. These low-cost incumbents set the bar for payer coverage and physician adoption that any new branded therapy must clear.
Large-cap cardiovascular pharma
Big pharmaceutical companies with cardiovascular and renal franchises (including firms developing therapies for CKD and heart failure) represent both competition for prescriber attention and potential acquirers or partners. Their scale in sales, trials, and payer negotiation contrasts with Mineralys's single-asset, clinical-stage profile.
How to invest in Mineralys Therapeutics, Inc. (MLYS)
There are three common ways to get MLYS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so MLYS sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where MLYS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Mineralys Therapeutics, Inc. (MLYS)
MLYS is a pre-commercial, single-asset hypertension biotech where the FDA decision on lorundrostat and its eventual launch, not current financials, define the outcome.
More on Mineralys Therapeutics, Inc. (MLYS)
Whether MLYS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MLYS a buy?, and where the stock could go from here in the MLYS stock forecast.
For income investors, whether MLYS pays a dividend and how the payout looks is covered in does MLYS pay a dividend?
Build a basket around MLYS with Walnut
Use Mineralys Therapeutics, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Mineralys Therapeutics (MLYS) do?
+
Mineralys is a clinical-stage biopharmaceutical company developing lorundrostat, an oral aldosterone synthase inhibitor for uncontrolled and resistant hypertension, with additional research in chronic kidney disease and obstructive sleep apnea. It is based in Radnor, Pennsylvania.
Does MLYS have any approved products or revenue?
+
No. As of mid-2026 Mineralys has no approved products and no product revenue. It is pre-commercial, funding operations from its cash balance while its lead drug lorundrostat is under FDA review.
What is the FDA decision date for lorundrostat?
+
The FDA accepted the lorundrostat New Drug Application and set a PDUFA target action date of December 22, 2026. That decision is the single most important near-term event for the company and the stock.
How much cash does Mineralys have?
+
Mineralys reported roughly $646 million in cash and investments as of March 31, 2026, and management has guided that this funds operations into 2028. The company also raised additional equity in June 2026.
Who are MLYS's main competitors?
+
The most direct competitor is AstraZeneca's baxdrostat, another late-stage aldosterone synthase inhibitor. Broader competition comes from cheap generic antihypertensives and mineralocorticoid receptor antagonists like spironolactone that dominate current hypertension treatment.
Why is MLYS considered a high-risk stock?
+
The company's value depends almost entirely on one drug, lorundrostat. A negative FDA decision, safety issue, competitive setback, or weak launch would hit hard because there is no product revenue or diversified pipeline to offset it, and the stock is highly volatile.
How is MLYS valued if it has no revenue?
+
Its roughly $2.3 billion market value reflects the market's probability-weighted view of lorundrostat's approval and future sales, not trailing earnings or revenue. Traditional multiples like price-to-earnings do not apply to a pre-revenue biotech.
What is lorundrostat's addressable market?
+
Lorundrostat targets uncontrolled and resistant hypertension, a very large patient population poorly served by existing generics, plus potential expansion into chronic kidney disease and obstructive sleep apnea. The size of that opportunity, weighed against approval and adoption risk, underpins the investment debate.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Mineralys Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.